PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India-Reference-Cited by-同舟云学术

PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India

Published:2017-10 Issue:10 Volume:39 Page:101042831771385
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumour Biol.

Author:

Guru Sameer Ahmad¹,Mir Rashid²,Bhat Musadiq¹,Najar Imtiyaz¹,Zuberi Mariyam¹,Sumi Mamta¹,Masroor Mirza¹,Gupta Naresh¹,Saxena Alpana¹

Affiliation:

1. Maulana Azad Medical College, New Delhi, India

2. Sher-i-Kashmir Institute of Medical Science, Srinagar, India

Publisher

IOS Press

Subject

General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1010428317713857

Reference29 articles.

1. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16‐year period

2. Chronic myelogenous leukemia in blast crisis

3. Definition of the accelerated phase of chronic myelogenous leukemia.

4. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival;BMC Cancer;2022-04-14

2. Risk of Thrombocytopenia With Platelet‐Derived Growth Factor Receptor Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta‐Analysis of Phase 2/3 Randomized, Controlled Trials;The Journal of Clinical Pharmacology;2021-08-02

3. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5;Human Cell;2020-07-14